

Chemical Constituents with GNMT-Promoter-Enhancing and NRF2-Reduction Activities from Taiwan Agarwood *Excoecaria formosana*

Ho-Cheng Wu ¹, Ming-Jen Cheng ², Chia-Hung Yen ^{1,3}, Yi-Ming Arthur Chen ^{4,5}, Yi-Siao Chen ⁶, Ih-Sheng Chen ⁷ and Hsun-Shuo Chang ^{1,3,7,8,*}

- ¹ Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan; duncanwu762001@gmail.com (H.-C.W.); chyen@kmu.edu.tw (C.-H.Y.)
 - ² Bioresource Collection and Research Center (BCRC), Food Industry Research and Development Institute (FIRDI), Hsinchu 300, Taiwan; cmj@firdi.org.tw (M.-J.C.)
 - ³ Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung 807, Taiwan
 - ⁴ Master Program in Clinical Pharmacogenomics and Pharmacoproteomics, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan; arthur@tmu.edu.tw (Y.-M.A.C.)
 - ⁵ Department of Medical Research and Education, Cheng Hsin General Hospital, Taipei 112, Taiwan
 - ⁶ Ph.D. Program in Environmental and Occupational Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan; dragonraja7992@yahoo.com.tw (Y.-S.C.)
 - ⁷ School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan; m635013@kmu.edu.tw (I.-S.C.)
 - ⁸ Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
- * Correspondence: hschang@kmu.edu.tw (H.-S.C.); Tel.: +886-7-312-1101 (ext. 2664)

The List of Supplementary Material

Figure A1. ¹ H NMR spectrum of (600 MHz, CDCl ₃) spectrum of 1	3
Figure A2. ¹³ C NMR spectrum of (150 MHz, CDCl ₃) spectrum of 1	3
Figure A3. DEPT spectrum of 1	4
Figure A4. COSY spectrum of 1	4
Figure A5. HMBC spectrum of 1	5
Figure A6. ROESY spectrum of 1	5
Figure A7. ¹ H NMR spectrum of (600 MHz, CD ₃ OD) spectrum of 2	6
Figure A8. ¹³ C NMR spectrum of (150 MHz, CD ₃ OD) spectrum of 2	6
Figure A9. DEPT spectrum of 2	7
Figure A10. COSY spectrum of 2	7
Figure A11. HMBC spectrum of 2	8
Figure A12. NOESY spectrum of 2	8
Figure A13. ¹ H NMR spectrum of (600 MHz, CD ₃ OD) spectrum of 3	9
Figure A14. ¹³ C NMR spectrum of (150 MHz, CD ₃ OD) spectrum of 3	9
Figure A15. DEPT spectrum of 3	10
Figure A16. COSY spectrum of 3	10
Figure A17. HMBC spectrum of 3	11
Figure A18. NOESY spectrum of 3	11
Figure A19. ¹ H NMR spectrum of (600 MHz, CD ₃ OD) spectrum of 4	12
Figure A20. ¹³ C NMR spectrum of (150 MHz, CD ₃ OD) spectrum of 4	12
Figure A21. DEPT spectrum of 4	13
Figure A22. COSY spectrum of 4	13
Figure A23. HMBC spectrum of 4	14
Figure A24. NOESY spectrum of 4	14
Table A1. GNMT-promoter-enhancing activity (Fold of induction) of compounds from the whole plant of <i>E. formosana</i>	15
Table A2. NRF2 inhibition in Huh7 cells of compounds from the whole plant of <i>E. formosana</i>	16
Phytochemical data of known compounds 5–44	17




Figure A1. ^1H NMR spectrum of (600 MHz, CDCl_3) spectrum of **1**




Figure A2. ^{13}C NMR spectrum of (150 MHz, CDCl_3) spectrum of **1**




Figure A3. DEPT spectrum of 1




Figure A4. COSY spectrum of 1

EFVPE-9-11-8-3-2-3-5
exp10 ROESY

```
SAMPLE          FLAGS
date Jan 22 2016 hs nn
solvent cdc13  sspul y
sample PFG1g    y
ACQUISITION
sw 8542.0 SPECIAL 5280
ae 0.150 temp 25.0
np 2882 gain 44
fb 4000 sp/in 0
ss 32 F2 PROCESSING 0
d1 1.500 gf 0.069
nt 40 gfs not used
2D ACQUISITION f0 4096
sw1 8542.0 F1 PROCESSING
ni 160 gf1 0.014
TRANSMITTER H1 procl not used
tn 597.300 fml 4096
sffq 597.3 DISPLAY
tpwr 58 sp -120.5
pw 12.000 wp 8089.5
TOCSY sp1 -122.4
mixR 0.600 wp1 8089.5
slpwr 45 rf1 5533.2
slpwr 56.750 rfp 4336.4
trim 0.0020 rf11 5530.4
PRESATURATION rfp1 4336.4
satmode n PLOT
wet n wc 140.0
DECOUPLER n sc 5.0
dn C13 wc2 140.0
dm nnn sc2 5.0
vs 132
th 2
ai cdc ph
```




Figure A5. HMBC spectrum of 1

EFVPE-9-11-8-3-2-3-5

Pulse Sequence: gHMBCAD




Figure A6. ROESY spectrum of 1




Figure A7. ¹H NMR spectrum of (600 MHz, CD₃OD) spectrum of 2




Figure A8. ¹³C NMR spectrum of (150 MHz, CD₃OD) spectrum of 2

EFWPE-11-15-10-3-4-A2

Pulse Sequence: gHMBCAD




Figure A11. HMBC spectrum of 2

EFWPE-11-15-10-3-4-A2

exp36 NOESY

```

SAMPLE          FLAGS      nn
date            Jun 5 2017   hs
solvent         cd3od        sspul   y
sample         PFGf1g        y
ACQUISITION     hsglv1       5352
  sw           9542.0        SPECIAL
  at           0.150        temp    30.0
  np           2862        gain     48
  rb           4000        spin    not used
  ss           32          F2 PROCESSING
  dl           1.200        gr       0.003
  nt           32          ofs     not used
2D ACQUISITION  fn          4098
  sv1          9542.0        F1 PROCESSING
  nl           160          gf1     0.013
  TRANSMITTER   H1          gf51   not used
  tn           597.297       plock  lp
  sfrq         597.3        fn1    4098
  tof          597.3        DISPLAY
  tpwr         59          sp      -121.1
  pw           11.800        wp     6089.5
  NOESY        sp1         -121.1
  mixN         0.600        wp1    6089.5
  PRESATURATION rf1       1183.4
  satmode      n          rfp     0
  wet          n          rf1    1183.4
  DECOUPLER    n          rf1    0
  dn           C13         PL0T    140.0
  dm          nnn         wc      5.0
                   sc     140.0
                   wc2   140.0
                   sc2    5.0
                   vs     1404
                   th
                   a1   cdc   ph   3

```




Figure A12. NOESY spectrum of 2




Figure A13. ^1H NMR spectrum of (600 MHz, CD_3OD) spectrum of **3**




Figure A14. ^{13}C NMR spectrum of (150 MHz, CD_3OD) spectrum of **3**




Figure A15. DEPT spectrum of 3

EFWPE-11-15-10-3-4-C2

exp35 gCOSY

SAMPLE	FLAGS	nn
date Jun 12 2017	hs	nn
solvent cd3od	ssu1	y
sample	hsglv1	5352
ACQUISITION	SPECIAL	
sw 9542.0	temp 30.0	
at 0.150	gain 52	
np 2882	spin not used	
fb 4000	F2 PROCESSING	
ss 32	sb -0.075	
d1 1.000	sbx not used	
nt 32	fn 4096	
2D ACQUISITION	F1 PROCESSING	
sw1 9542.0	sb1 -0.013	
ni 160	sbx1 not used	
d2 0	prcl1 lg	
PRESATURATION	fn1	4096
satmode	n	DISPLAY
wet	sp	-121.2
TRANSMITTER	wp	6089.5
tn H1	sp1	-121.2
sfrq 597.297	wp1	6089.5
tof 597.3	rf1	1183.4
tpwr 53	rfp	0
pw 11.800	rf11	1183.4
GRADIENTS	rrf1	0
g2lv1e 4464	PLOT	
gtf 0.001000	wc 140.0	
Edratio 1.000	sc 5.0	
gstab 0.000500	wc2 140.0	
DECOUPLER	sc2 5.0	
dn C13	vs 8317	
dm nnn	th 7	
	at av	




Figure A16. COSY spectrum of 3

EFWPE-11-15-10-3-4-C2

Pulse Sequence: gHMBCAD




Figure A17. HMBC spectrum of 3

EFWPE-11-15-10-3-4-C2

Pulse Sequence: NOESY




Figure A18. NOESY spectrum of 3




Figure A19. ^1H NMR spectrum of (600 MHz, CD_3OD) spectrum of **4**




Figure A20. ^{13}C NMR spectrum of (150 MHz, CD_3OD) spectrum of **4**




Figure A21. DEPT spectrum of 4




Figure A22. COSY spectrum of 4

EFWPE-10-8-4-8-2

Pulse Sequence: gHMBCAD




Figure A23. HMBC spectrum of 4

EFWPE-10-8-4-8-2

exp36 NOESY

```
date Mar 24 2017 hs nn
solvent cd3od sspul y
sample PFGTg hsglv y
ACQUISITION 5352
sw 9542.0 SPECIAL
at 0.150 temp 30.0
np 2882 gain 48
fb 4000 spin not used
ss 32 F2 PROCESSING
d1 1.500 gf 0.069
nt 48 gfs not used
2D ACQUISITION fn 4096
swl 9542.0 F1 PROCESSING
nl 160 gf1 0.013
TRANSMITTER H1 gfs1 not used
tn H1 proc1 lp
sfrq 597.297 fn1 4096
tof 597.3 DISPLAY
tpwr 59 sp -121.1
pw 11.800 wp 6089.5
NOESY 0.600 spl -121.1
mixN PRESATURATION rf1 1183.4
satmode n rfp 0
wet n rf1 1183.4
DECOUPLER n rfpl 0
dn C13 PLOT
dm nnn wc 140.0
sc 5.0
wc2 140.0
sc2 5.0
vs 607
th
al cdc ph 3
```




Figure A24. NOESY spectrum of 4

Table A1. GNMT-promoter-enhancing activity (Fold of induction) of compounds from the whole plant of *E. formosana*

Compound ^a	Activity (Fold of induction) ^b	Compound ^a	Activity (Fold of induction) ^b
1	1.11±0.05	26	0.67±0.02
2	1.28±0.02	27	1.02±0.11
3	1.39±0.16	28	0.42±0.04
4	1.20±0.06	29	0.96±0.04
5	1.04±0.03	31	0.06±0.007
6	2.14±0.06	32	1.17±0.05
7	1.09±0.10	33 & 34	0.36±0.12
9	0.58±0.09	35 & 36	0.74±0.08
10	1.32±0.02	37	1.23±0.15
12	0.90±0.15	38	2.97±0.27
13-16	0.68±0.09	39	1.28±0.05
17	0.94±0.03	40	3.17±1.03
18	0.83±0.05	41	2.73±0.23
19	1.29±0.05	42	2.63±0.14
20	1.46±0.07	43	6.57±0.13
22	0.68±0.07	44	2.62±0.05
24	0.91±0.10	PGG ^c	4.45±0.26
25	0.81±0.04		

^aSample concentration is 100 μM. ^bGNMT promoter activity (Fold of induction) = observed activity/solvent control activity. ^cPGG = 1,2,3,4,6-penta-*O*-galloyl-β-D-glucose was used as a positive control for GNMT activation with 100 μM.

Table A2. NRF2 inhibition in Huh7 cells of compounds from the whole plant of *E. formosana*

Compound ^a	Activity (Fold of induction) ^b	Compound ^a	Activity (Fold of induction) ^b
1	60.5±1.5	26	69.9±0.3
2	81.9±8.1	27	101.8±1.5
3	89.7±2.1	28	83.0±2.3
4	93.5±3.9	29	104.5±9.2
5	89.2±4.5	31	88.8±3.5
6	91.8±1.1	32	84.7±4.0
7	79.4±5.1	33 & 34	93.3±3.7
9	93.2±0.7	35 & 36	99.2±1.4
10	85.6±5.9	37	109.7±1.7
12	80.4±1.9	38	75.7±0.9
13-16	NT ^c	39	95.7±2.5
17	89.8±1.5	40	33.1±0.2
18	116.2±2.7	41	67.8±3.9
19	91.5±5.1	42	59.2±2.9
20	91.3±2.4	43	45.2±2.5
22	103.7±2.8	44	73.0±2.5
24	104.9±2.6	Retinoic acid ^d	34.2±1.4
25	110.0±5.3		

^aSample concentration is 100 μ M. ^bRelative NRF2 activity was presented as the percentage to solvent control. ^cNT, None tested. ^dRetinoic acid was used as a positive control for Nrf2 inhibition with 1 μ M.

Phytochemical data of known compounds 5–44

Deglucosyl lauroside B (5): Colorless oil; $[\alpha]^{26}_D$: -15 (c 0.16, MeOH); IR ν_{\max} (ATR) 3381 (OH), 1698 (C=O) cm^{-1} ; ^1H NMR (CD_3OD , 600 MHz) δ : 0.909 (3H, s, H-12), 0.914 (3H s, H-11), 1.28 (3H, d, $J = 6.3$ Hz, H-10), 1.83 (1H, dd, $J = 13.8, 2.1$ Hz, H-2b), 2.18 (1H, dddd, $J = 14.1, 4.8, 4.8, 3.0$ Hz, H-5), 2.26 (1H, ddd, $J = 14.1, 4.8, 2.1$ Hz, H-4b), 2.83 (1H, t, $J = 14.1$ Hz, H-4a), 2.93 (1H, d, $J = 13.8$ Hz, H-2a), 3.59 (1H, dd, $J = 11.4, 3.0$ Hz, H-13b), 3.84 (1H, dd, $J = 11.4, 4.8$ Hz, H-13a), 4.36 (1H, quint, $J = 6.3, 1.2$ Hz, H-9), 5.75 (1H, dd, $J = 15.6, 1.2$ Hz, H-7), 5.95 (1H, dd, $J = 15.6, 6.3$ Hz, H-8); ESI-MS m/z : 265 $[\text{M}+\text{Na}]^+$

Gallic acid (6): Colorless needles (CH_2Cl_2 -MeOH); IR ν_{\max} (ATR) 3107 (OH), 1684 (C=O), 1612, 1539 (aromatic ring) cm^{-1} ; ^1H NMR (acetone- d_6 , 400 MHz) δ : 7.15 (2H, s, H-2 and H-6); ^{13}C NMR (acetone- d_6 , 100 MHz) δ : 110.2 (C-2 and C-6), 122.2 (C-1), 138.7 (C-4), 146.1 (C-3 and C-5), 167.7 (C-7); ESI-MS m/z : 193 $[\text{M}+\text{Na}]^+$

Methyl gallate (7): Colorless needles (CH_2Cl_2 -MeOH); IR ν_{\max} (ATR) 3464 (OH), 1686 (C=O), 1617, 1542, 1438 (aromatic ring) cm^{-1} ; ^1H NMR (acetone- d_6 , 400 MHz) δ : 3.78 (3H, s, OCH_3), 7.11 (2H, s, H-2 and H-6); ^{13}C NMR (acetone- d_6 , 100 MHz) δ : 51.1 (OCH_3), 108.9 (C-2 and C-6), 120.9 (C-1), 137.9 (C-4), 145.2 (C-3 and C-5), 166.4 (C=O); ESI-MS m/z : 185 $[\text{M}+\text{H}]^+$

4-Methoxybenzoic acid (8): Colorless oil; UV (MeOH) λ_{\max} ($\log \epsilon$) 210 (3.72), 255 (3.57) nm; IR ν_{\max} (ATR) 3436 (OH), 1710 (C=O), 1607, 1441 (aromatic ring) cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz) δ : 3.88 (3H, s, OCH_3 -4), 6.85 (2H, d, $J = 8.8$ Hz, H-3 and H-5), 7.96 (2H, d, $J = 8.8$ Hz, H-2 and H-6); ESI-MS m/z : 153 $[\text{M}+\text{H}]^+$

3-Hydroxy-1-(3,5-dimethoxy-4-hydroxyphenyl)propan-1-one (9): Whitish powder; UV (MeOH) λ_{\max} ($\log \epsilon$) 216 (3.55), 234 (3.41), 298 (3.30) nm; IR ν_{\max} (ATR) 3370 (OH), 1659 (C=O), 1591, 1515, 1453 (aromatic ring) cm^{-1} ; ^1H NMR (CD_3OD , 400 MHz) δ : 3.17 (2H, t, $J = 4.2$ Hz, H-8), 3.90 (6H, s, OCH_3 -2 and OCH_3 -6), 3.95 (2H, t, $J = 4.2$ Hz, H-9), 7.32 (2H, s, H-3 and H-5); ^{13}C NMR (CD_3OD , 100 MHz) δ : 41.7 (C-8), 56.9 (OCH_3 -2 and OCH_3 -6), 59.1 (C-9), 107.6 (C-3 and C-5), 129.2 (C-1), 144.9 (C-4), 149.5 (C-2 and C-6), 200.0 (C-7); ESI-MS m/z : 227.17 $[\text{M}+\text{H}]^+$

3-Hydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-1-one (10): Yellowish solid; UV (MeOH) λ_{\max} ($\log \epsilon$) 205 (4.11), 228 (3.77), 275 (3.66) nm; IR ν_{\max} (ATR) 3310 (OH), 1659 (C=O), 1591, 1516, 1453 (aromatic ring) cm^{-1} ; IR ν_{\max} (ATR) 3310 (OH), 1714 (C=O) cm^{-1} ; ^1H NMR (CD_3OD , 600 MHz) δ : 3.16 (2H, t, $J = 6.2$ Hz, H-8), 3.90 (3H, s, OCH_3 -2), 3.94 (2H, t, $J = 6.2$ Hz, H-9), 6.87 (1H, d, $J = 8.0$ Hz, H-6), 7.55 (1H, d, $J = 2.0$ Hz, H-3), 7.58 (1H, dd, $J = 8.0, 2.0$ Hz, H-5); ^{13}C NMR (CD_3OD , 150 MHz) δ : 41.7 (C-8), 56.4 (OCH_3 -2), 59.0 (C-9), 112.0 (C-3), 115.8 (C-6), 124.7 (C-5), 130.7 (C-4), 149.1 (C-2), 153.4 (C-1), 199.7 (C-7); ESI-MS m/z : 197 $[\text{M}+\text{H}]^+$

2,3-Dihydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-1-one (11): Whitish solid; UV (MeOH) λ_{\max} ($\log \epsilon$) 205 (3.66), 280 (3.25) nm; IR ν_{\max} (ATR) 3327 (OH), 1664 (C=O), 1590, 1517, 1424 (aromatic ring) cm^{-1} ; ^1H NMR (CD_3OD , 400 MHz) δ : 3.73 (1H, dd, $J = 11.7, 5.2$ Hz, H-9b), 3.89 (1H, dd, $J = 11.7, 3.9$ Hz, H-9a), 3.92 (3H, s, OCH_3 -2), 5.11 (1H, dd, $J = 5.2, 3.9$ Hz, H-8), 6.88 (1H, d, $J = 8.4$ Hz, H-6), 7.58 (1H, d, $J = 2.0$ Hz, H-3), 7.59 (1H, dd, $J = 8.4, 2.0$ Hz, H-5); ESI-MS m/z : 213 $[\text{M}+\text{H}]^+$

(2S,3R)-4E-Dehydrochebulic acid trimethyl ester (12): Colorless needles; $[\alpha]^{26}_D$: -34 (c 0.205, MeOH); UV (MeOH) λ_{\max} ($\log \epsilon$) 220 (4.34), 285 (3.80) nm; IR ν_{\max} (ATR) 3400 (OH), 1712 (C=O), 1608, 1492, 1438 (aromatic ring) cm^{-1} ; ^1H NMR (acetone- d_6 , 400 MHz) δ : 3.62 (3H, s, OCH_3 -6 or OCH_3 -7), 3.63 (3H, s, OCH_3 -7 or OCH_3 -6), 3.67 (3H, s, OCH_3 -1), 5.27 (1H, d, $J = 1.4$ Hz, H-2), 5.40 (1H, d, $J = 1.4$ Hz, H-3), 6.81 (1H, s, H-5), 7.13 (1H, s, H-3'); ^{13}C NMR (acetone- d_6 ,

100 MHz) δ : 36.0 (C-3), 53.0 (OCH₃-6 or OCH₃-7), 53.4 (OCH₃-7 or OCH₃-6), 53.8 (OCH₃-1), 79.8 (C-2), 109.3 (C-3'), 116.7 (C-1'), 119.2 (C-2'), 130.4 (C-5), 139.6 (C-4'), 143.5 (C-4), 144.3 (C-6'), 146.7 (C-5'), 164.3 (C-7'), 166.7 (C-6), 167.6 (C-7), 171.1 (C-1); ESI-MS m/z : 397 [M+H]⁺

A mixture of gynuramides I-IV (13~16): Whitish solid; $[\alpha]^{26}_D$: +11 (*c* 0.75, pyridine); IR ν_{\max} (ATR) 3338 (OH), 1633 (amide) cm⁻¹; ¹H NMR (pyridine-*d*₅, 400 MHz) δ : 0.87 (6H, t, *J* = 7.4 Hz, terminal methyl), 1.76 (2H, m, H-11), 2.00 (2H, m, H-7), 2.07 (1H, m, H-3'b), 2.13 (2H, m, H-5), 2.16 (2H, m, H-10), 2.31 (1H, m, H-3'a), 4.29 (1H, m, H-4), 4.36 (1H, m, H-3), 4.43 (1H, dd, *J* = 10.8, 4.8 Hz, H-1b), 4.52 (1H, dd, *J* = 10.8, 4.8 Hz, H-1a), 4.63 (1H, dd, *J* = 7.8, 3.8 Hz, H-2'), 5.13 (1H, quint, *J* = 4.8 Hz, H-2), 5.52 (2H, m, H-8 and H-9), 8.60 (1H, d, *J* = 9.2 Hz, NH); ¹³C NMR (pyridine-*d*₅, 100 MHz) δ : 14.3 (terminal methyl), 22.9 (C-17), 25.8 (C-11), 26.7 (C-4' and C-6), 29.5~30.2 (all CH₂), 32.1 (C-16), 32.9 (C-7), 33.3 (C-10), 33.8 (C-5), 35.7 (C-3'), 52.9 (C-2), 61.9 (C-1), 72.4 (C-2'), 72.9 (C-4), 76.8 (C-3), 130.7 (C-9), 130.8 (C-8), 175.3 (C-1'); gynuramide I (**13**): 718 [M+Na]⁺, gynuramide II (**14**): 704 [M+Na]⁺, gynuramide III (**15**): 690 [M+Na]⁺, gynuramide IV (**16**): 676 [M+Na]⁺

Scopoletin (17): Yellowish powder; UV (MeOH) λ_{\max} (log ϵ) 209 (4.19), 228 (4.04), 262 (3.53), 297 (3.61), 344 (3.94) nm; IR ν_{\max} (ATR) 3335 (OH), 1702 (C=O), 1607, 1564, 1511 (aromatic ring) cm⁻¹; ¹H NMR (acetone-*d*₆, 400 MHz) δ : 3.89 (3H, s, OCH₃-6), 6.14 (1H, d, *J* = 9.4 Hz, H-3), 6.78 (1H, s, H-8), 7.17 (1H, s, H-5), 7.83 (1H, d, *J* = 9.4 Hz, H-4); ESI-MS m/z : 193 [M+H]⁺

Fraxetin (18): Yellowish solid; UV (MeOH) λ_{\max} (log ϵ) 210 (4.4), 340 (3.86) nm; IR ν_{\max} (ATR) 3360 (OH), 1680 (C=O), 1575, 1508, 1456 (aromatic ring) cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ : 3.90 (3H, s, OCH₃-7), 6.21 (1H, d, *J* = 9.6 Hz, H-3), 6.72 (1H, s, H-8), 7.84 (1H, d, *J* = 9.6 Hz, H-4); ESI-MS m/z : 209 [M+H]⁺

6-Hydroxy-5,7-dimethoxycoumarin (19): Yellowish powder; IR ν_{\max} (ATR) 3402 (OH), 1711 (C=O), 1580, 1459, 1415 (aromatic ring) cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ : 3.85 (3H, s, H-7), 3.90 (3H, s, H-5), 6.00 (1H, d, *J* = 9.2 Hz, H-3), 6.77 (1H, s, H-8), 7.79 (1H, d, *J* = 9.2 Hz, H-4); ESI-MS m/z : 223 [M+H]⁺

Cleomiscosin A (20): Whitish solid; UV (MeOH) λ_{\max} (log ϵ) 205 (4.69), 325 (4.02) nm; IR ν_{\max} (ATR) 3308 (OH), 1696 (C=O), 1612, 1571, 1523, 1447 (aromatic ring) cm⁻¹; ¹H NMR (pyridine-*d*₅, 400 MHz) δ : 3.71 (3H, s, OCH₃-3'), 3.80 (3H, s, OCH₃-6), 3.91 (1H, ddd, *J* = 13.0, 6.0, 2.4 Hz, H-9'b), 4.32 (1H, ddd, *J* = 13.0, 6.0, 2.4 Hz, H-9'a), 4.48 (1H, dt, *J* = 8.2, 2.4 Hz, H-8'), 5.59 (1H, d, *J* = 8.2 Hz, H-7'), 6.44 (1H, d, *J* = 9.4 Hz, H-3), 6.73 (1H, s, H-5), 7.30 (1H, d, *J* = 8.0 Hz, H-5'), 7.36 (1H, dd, *J* = 8.2, 2.0 Hz, H-6'), 7.42 (1H, d, *J* = 2.0 Hz, H-2'), 7.55 (1H, t, *J* = 6.0 Hz, OH-9', D₂O exchangeable), 7.75 (1H, d, *J* = 9.4 Hz, H-4), 11.19 (1H, s, OH-4', D₂O exchangeable); ESI-MS m/z 409 [M+Na]⁺

Cleomiscosin B (21): Whitish solid; UV (MeOH) λ_{\max} (log ϵ) 205 (4.69), 325 (4.02) nm; IR ν_{\max} (ATR) 3424 (OH), 1708 (C=O), 1614, 1572, 1520, 1448 (aromatic ring) cm⁻¹; ¹H NMR (pyridine-*d*₅, 400 MHz) δ : 3.71 (3H, s, OCH₃-3'), 3.83 (3H, s, OCH₃-6), 3.94 (1H, ddd, *J* = 12.7, 7.1, 3.5 Hz, H-9'b), 4.28 (1H, ddd, *J* = 12.7, 5.3, 2.3 Hz, H-9'a), 4.53 (1H, ddd, *J* = 8.0, 3.5, 2.3 Hz, H-7'), 5.55 (1H, d, *J* = 8.0 Hz, H-8'), 6.40 (1H, d, *J* = 9.6 Hz, H-3), 6.74 (1H, s, H-5), 7.25 (1H, dd, *J* = 7.1, 5.3 Hz, OH-9', D₂O exchangeable), 7.30 (1H, d, *J* = 8.0 Hz, H-5'), 7.36 (1H, dd, *J* = 8.0, 2.0 Hz, H-6'), 7.43 (1H, d, *J* = 2.0 Hz, H-2'), 7.72 (1H, d, *J* = 9.6 Hz, H-4); ESI-MS m/z 409 [M+Na]⁺

Cleomiscosin C (22): Whitish solid; IR ν_{\max} (ATR) 3381 (OH), 1698 (C=O), 1612, 1573, 1460 (aromatic ring) cm⁻¹; ¹H NMR (pyridine-*d*₅, 400 MHz) δ : 3.79 (6H, s, OCH₃-3' and OCH₃-5'), 3.81 (3H, s, OCH₃-6), 3.94 (1H, br d, *J* = 13.8 Hz, H-9'b), 4.34 (1H, br d, *J* = 13.8 Hz, H-9'a), 4.52 (1H, dt, *J* = 8.1, 2.5 Hz, H-8'), 5.61 (1H, d, *J* = 8.1 Hz, H-7'), 6.46 (1H, d, *J* = 9.3 Hz, H-3), 6.75 (1H, s, H-

5), 7.22 (2H, s, H-2' and H-6'), 7.60 (1H, br s, OH-9', D₂O exchangeable), 7.76 (1H, d, $J = 9.3$ Hz, H-4), 11.09 (1H, s, OH-4', D₂O exchangeable); ESI-MS m/z 439 [H+Na]⁺

Cleomiscosin D (23): Whitish solid; ¹H NMR (pyridine-*d*₅, 400 MHz) δ : 3.78 (6H, s, OCH₃-3' and OCH₃-5'), 3.83 (3H, s, OCH₃-6), 3.97 (1H, br d, $J = 11.8$ Hz, H-9'b), 4.30 (1H, br d, $J = 11.8$ Hz, H-9'a), 4.57 (1H, ddd, $J = 8.0, 3.3, 2.1$ Hz, H-7'), 5.56 (1H, d, $J = 8.0$ Hz, H-8'), 6.41 (1H, d, $J = 9.4$ Hz, H-3), 6.74 (1H, s, H-5), 7.21 (1H, s, H-2' and H-6'), 7.74 (1H, d, $J = 9.4$ Hz, H-4); ESI-MS m/z 439 [M+Na]⁺

Malloapelin A (24): Yellowish solid; IR ν_{\max} (ATR) 3354 (OH), 1698 (C=O), 1619, 1575, 1523 (aromatic ring) cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ : 3.57 (1H, dd, $J = 12.8, 4.0$ Hz, H-9'b), 3.86 (1H, dd, $J = 12.8, 2.5$ Hz, H-9'a), 3.87 (3H, s, OCH₃-3'), 4.18 (1H, ddd, $J = 8.0, 4.0, 2.5$ Hz, H-8'), 5.00 (1H, d, $J = 8.0$ Hz, H-7'), 6.27 (1H, d, $J = 9.8$ Hz, H-3), 6.64 (1H, s, H-5), 6.64 (1H, d, $J = 1.6$, H-6'), 6.67 (1H, d, $J = 2.0$ Hz, H-2'), 7.80 (1H, d, $J = 9.8$ Hz, H-4); ESI-MS m/z 389 [M+H]⁺

Malloapelin B (25): Whitish solid; IR ν_{\max} (ATR) 3342 (OH), 1696 (C=O), 1618, 1575, 1520 (aromatic ring) cm⁻¹; ¹H NMR (CD₃OD, 400 MHz) δ : 3.62 (1H, dd, $J = 12.4, 6.0$ Hz, H-9'b), 3.70 (1H, dd, $J = 12.4, 2.7$ Hz, H-9'a), 3.86 (3H, s, OCH₃-3'), 4.22 (1H, ddd, $J = 8.2, 6.0, 2.7$ Hz, H-7'), 4.87 (1H, d, $J = 8.2$ Hz, H-8'), 6.26 (1H, d, $J = 9.4$ Hz, H-3), 6.60 (1H, d, $J = 2.0$, H-6'), 6.63 (1H, d, $J = 2.0$ Hz, H-2'), 6.65 (1H, s, H-5), 7.81 (1H, d, $J = 9.4$ Hz, H-4); ESI-MS m/z 389 [M+H]⁺

ent-11- α -Hydroxy-3-oxo-13-epi-manoyl oxide (26): Whitish powder; $[\alpha]_{\text{D}}^{26}$: -41 (*c* 0.095, CHCl₃); IR ν_{\max} (ATR) 3439 (OH), 1700 (C=O), 1124 (ether) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ : 1.01 (3H, s, H-20), 1.04 (3H, s, H-19), 1.11 (3H, s, H-18), 1.24 (3H, s, H-16), 1.27 (3H, s, H-17), 1.38 (1H, d, $J = 10.0$ Hz, H-9), 1.47 (2H, m, H-6b and H-7b), 1.58 (1H, m, H-12b), 1.62 (1H, m, H-5), 1.63 (1H, m, H-6a), 1.76 (1H, m, H-1b), 1.81 (1H, m, H-7a), 2.49 (2H, m, H-2), 2.50 (1H, m, H-12a), 2.52 (1H, m, H-1a), 4.17 (1H, ddd, $J = 10.0, 9.6, 4.4$ Hz, H-11), 4.96 (1H, br d, $J = 11.2$ Hz, H-15b), 5.08 (1H, d, $J = 17.8$ Hz, H-15a), 6.00 (1H, br dd, $J = 17.8, 11.2$ Hz, H-14); ¹³C NMR (CDCl₃, 100 MHz) δ : 16.1 (C-20), 20.8 (C-6 and 19), 24.7 (C-17), 27.0 (C-18), 32.3 (C-16), 33.9 (C-2), 38.0 (C-10), 40.3 (C-1), 42.4 (C-7), 45.3 (C-12), 47.6 (C-4), 54.8 (C-5), 62.6 (C-9), 65.7 (C-11), 74.2 (C-13), 76.7 (C-8), 110.0 (C-15), 147.6 (C-14), 217.6 (C-3); ESI-MS m/z : 321 [M+H]⁺

Excoecafolin D (27): Whitish solid; $[\alpha]_{\text{D}}^{26}$: -28 (*c* 0.39, pyridine); IR ν_{\max} (ATR) 3364 (OH), 1692 (C=O) cm⁻¹; ¹H NMR (acetone-*d*₆, 400 MHz) δ : 0.94 (3H, d, $J = 6.8$ Hz, H-18), 1.68 (1H, dd, $J = 3.6, 2.0$ Hz, H-12b), 1.71 (3H, q, $J = 1.2$ Hz, H-19), 1.79 (3H, dd, $J = 1.2, 0.6$ Hz, H-17), 1.92 (1H, br t, $J = 13.4$ Hz, H-12a), 2.19 (1H, ddd, $J = 13.4, 6.6, 3.6$ Hz, H-11), 3.25 (1H, d, $J = 2.0$ Hz, H-8), 3.32 (1H, s, H-7), 3.44 (1H, dd, $J = 7.2, 6.0$ Hz, OH-20, D₂O exchangeable), 3.55 (1H, dd, $J = 12.0, 7.2$ Hz, H-20b), 3.82 (1H, s, OH-13, D₂O exchangeable), 3.93 (1H, dd, $J = 12.0, 6.0$ Hz, H-20a), 4.07 (1H, m, H-14), 4.09 (1H, m, H-10), 4.18 (1H, dd, $J = 4.4, 0.8$ Hz, H-5), 4.47 (1H, d, $J = 4.4$ Hz, OH-5, D₂O exchangeable), 4.71 (1H, d, $J = 0.8$ Hz, OH-9, D₂O exchangeable), 4.96 (1H, quintet, $J = 1.2$ Hz, H-16b), 5.06 (1H, br s, H-16a), 5.16 (1H, d, $J = 5.2$ Hz, OH-4, D₂O exchangeable), 5.30 (1H, s, OH-14, D₂O exchangeable), 7.62 (1H, quintet, $J = 1.2$ Hz, H-1); ESI-MS m/z 397 [M+H]⁺

Agallochin I (28): Colorless oil; $[\alpha]_{\text{D}}^{26}$: -41 (*c* 0.215, MeOH); IR ν_{\max} (ATR) 3382 (OH) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz) δ : 1.00 (1H, m, H-5), 1.01 (3H, s, H-17), 1.03 (1H, m, H-11b), 1.08 (1H, m, H-14b), 1.13 (1H, m, H-9), 1.14 (3H, d, $J = 7.0$ Hz, H-18), 1.21 (1H, m, H-1b), 1.22 (2H, m, H-12), 1.37 (1H, t, $J = 12.4$ Hz, H-7b), 1.56 (1H, dd, $J = 10.0, 2.4$ Hz, H-14a), 1.63 (1H, m, H-11a), 1.72 (1H, m, H-2b), 1.87 (1H, dd, $J = 12.4, 4.0$ Hz, H-7a), 1.95 (1H, qd, $J = 7.0, 2.4$ Hz, H-4), 2.03 (1H, dt, $J = 13.2, 3.3$ Hz, H-2a), 2.06 (1H, dt, $J = 12.0, 3.3$ Hz, H-1a), 3.84 (2H, d, $J = 3.2$ Hz, H-19), 3.82 (1H, d, $J = 1.2$ Hz, H-6), 5.50 (1H, d, $J = 5.6$ Hz, H-16), 5.56 (1H, d, $J = 5.6$ Hz, H-15); ¹³C NMR (CDCl₃, 100 MHz) δ : 19.3 (C-18), 20.8 (C-11), 24.5 (C-17), 27.5 (C-2), 31.6 (C-1), 32.1 (C-12), 36.5 (C-10), 42.2 (C-4), 43.7 (C-13), 44.6 (C-9), 45.2 (C-7), 49.5 (C-8), 57.1 (C-5), 60.5 (C-14), 68.7 (C-19), 70.5 (C-6), 97.8 (C-3), 133.2 (C-15), 138.1 (C-16); ESI-MS m/z 305 [M+H]⁺

(+)-Catechin (29): Whitish powder; $[\alpha]^{23}_D$: +130 (*c* 0.48, MeOH); IR ν_{\max} (ATR) 3317 (OH), 1521, 1462 (aromatic ring) cm^{-1} ; $^1\text{H NMR}$ (CD_3OD , 400 MHz) δ : 2.51 (1H, dd, $J = 16.0, 2.0$ Hz, H-4a), 2.85 (1H, dd, $J = 16.0, 5.6$ Hz, H-4b), 3.98 (1H, ddd, $J = 7.6, 5.6, 2.0$ Hz, H-3), 4.57 (1H, d, $J = 7.6$ Hz, H-2), 5.86 (1H, d, $J = 2.4$ Hz, H-6), 5.94 (1H, d, $J = 2.4$ Hz, H-8), 6.72 (1H, dd, $J = 8.2, 2.0$ Hz, H-6'), 6.77 (1H, d, $J = 8.2$ Hz, H-5'), 6.83 (1H, d, $J = 2.0$ Hz, H-2'); ESI-MS m/z 291 $[\text{M}+\text{H}]^+$

Kaempferol-3-O- β -D-glucoside (30): Yellowish solids; $^1\text{H NMR}$ (CD_3OD , 600 MHz) δ : 3.20 (1H, m, H-3''), 3.30 (1H, m, H-4''), 3.41 (1H, m, H-5''), 3.44 (1H, m, H-2''), 3.53 (1H, dd, $J = 12.0, 5.4$ Hz, H-6''b), 3.68 (1H, dd, $J = 12.0, 2.4$ Hz, H-6''a), 5.20 (1H, d, $J = 7.2$ Hz, H-1''), 6.17 (1H, d, $J = 1.8$ Hz, H-6), 6.35 (1H, d, $J = 1.8$ Hz, H-8), 6.89 (2H, dd, $J = 9.0, 2.4$ Hz, H-3' and H-5'), 8.05 (2H, dd, $J = 9.0, 2.4$ Hz, H-2' and H-6'); ESI-MS m/z 449 $[\text{M}+\text{H}]^+$

6'-(Stigmast-5-en-7-one-3-O- β -glucopyransidyl)hexadecanoate (31): Whitish solid; $[\alpha]^{23}_D$: -81 (*c* 0.10, CHCl_3); IR ν_{\max} (ATR) 3371 (OH), 1732 (C=O), 1670 (C=O) cm^{-1} ; $^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ : 0.67 (3H, s, H-18), 0.81 (3H, d, $J = 7.2$ Hz, H-26), 0.83 (3H, d, $J = 7.6$ Hz, H-27), 0.84 (3H, t, $J = 6.8$ Hz, H-16''), 0.87 (3H, t, $J = 6.8$ Hz, H-29), 0.92 (3H, d, $J = 6.8$ Hz, H-21), 1.18 (3H, s, H-19), 1.58 (2H, m, H-3''), 2.23 (1H, t, $J = 11.4$ Hz, H-8), 2.33 (2H, t, $J = 7.6$ Hz, H-2''), 2.59 (1H, m, H-12), 3.36 (1H, t, $J = 8.8$ Hz, H-4'), 3.36 (1H, t, $J = 8.8$ Hz, H-2'), 3.47 (1H, m, H-5'), 3.56 (1H, t, $J = 8.8$ Hz, H-3'), 3.66 (1H, m, H-3), 3.71 (1H, OH, D_2O -exchangeable), 3.86 (1H, OH, D_2O -exchangeable), 4.28 (1H, br d, $J = 10.6$ Hz, H-6'b), 4.39 (1H, br d, $J = 7.6$ Hz, H-1'), 4.40 (1H, br d, $J = 7.6$ Hz, H-6'a), 5.70 (1H, d, $J = 0.8$ Hz, H-6); $^{13}\text{C NMR}$ (CDCl_3 , 100 MHz) δ : 11.9 (C-18 and C-29), 14.1 (C-16''), 17.2 (C-19), 18.9 (C-21), 19.0 (C-27), 19.8 (C-26), 21.2 (C-15), 22.7 (C-11 and C-15''), 23.0 (C-28), 25.0 (C-3''), 26.1 (C-23), 26.3 (C-16), 28.5 (C-2), 29.1 (C-25), 29.2~29.7 (C-4''~C-13''), 31.9 (C-14''), 33.9 (C-22), 34.2 (C-2''), 36.1 (C-20), 36.3 (C-1), 38.4 (C-10), 38.7 (C-4 & C-12), 43.1 (C-13), 45.4 (C-8), 45.7 (C-24), 49.88 (C-14), 49.90 (C-29), 54.7 (C-17), 63.3 (C-6'), 70.1 (C-4'), 73.4 (C-2'), 73.9 (C-5'), 76.0 (C-3'), 78.3 (C-3), 101.5 (C-1'), 126.3 (C-6), 164.8 (C-5), 174.5 (C-1''), 202.3 (C-7); ESI-MS m/z : 829 $[\text{M}+\text{H}]^+$

(6'-O-Palmitoyl)sitosterol-3-O- β -D-glucoside (32): Whitish solid; $[\alpha]^{25}_D$: -50 (*c* 0.28, CHCl_3); IR ν_{\max} (ATR) 3401 (OH), 1736 (C=O) cm^{-1} ; $^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ : 0.68 (3H, s, H-18), 0.81 (3H, d, $J = 7.2$, H-27), 0.84 (3H, t, $J = 7.2$, H-26), 0.86 (3H, t, $J = 7.4$, H-29), 0.88 (3H, t, $J = 6.8$, H-17''), 0.92 (3H, d, $J = 6.4$, H-21), 1.00 (3H, s, H-19), 2.34 (2H, t, $J = 7.6$, H-2''), 2.63 (1H, OH, D_2O -exchangeable), 3.05 (1H, OH, D_2O -exchangeable), 3.20 (1H, OH, D_2O -exchangeable), 3.37 (1H, m, H-2'), 3.39 (1H, m, H-4'), 3.45 (1H, m, H-5'), 3.53 (1H, m, H-3), 3.59 (1H, m, H-3'), 4.28 (1H, dd, $J = 12.0, 2.0$, H-6'b), 4.38 (1H, d, $J = 7.6$, H-1'), 4.40 (1H, dd, $J = 12.0, 4.8$, H-6'a), 5.36 (1H, d, $J = 5.2$, H-6); $^{13}\text{C NMR}$ (CDCl_3 , 100 MHz) δ : 11.8 (C-18), 12.0 (C-29), 14.1 (C-17''), 18.8 (C-21), 19.0 (C-27), 19.3 (C-19), 19.8 (C-26), 21.0 (C-11), 22.7 (C-16''), 23.0 (C-28), 24.3 (C-15), 24.9 (C-3''), 26.0 (C-23), 28.2 (C-16), 29.1 (C-2), 29.2 (C-25), 29.2~29.7 (C-4''~C-14''), 31.8 (C-8), 31.9 (C-7 & C-15''), 33.9 (C-22), 34.2 (C-2''), 36.1 (C-20), 36.7 (C-10), 37.2 (C-1), 38.9 (C-4), 39.7 (C-12), 42.3 (C-13), 45.8 (C-24), 50.1 (C-9), 56.0 (C-17), 56.7 (C-14), 63.2 (C-6'), 70.0 (C-4'), 73.5 (C-2'), 73.9 (C-5'), 75.9 (C-3'), 79.6 (C-3), 101.2 (C-1'), 122.2 (C-6), 140.2 (C-5), 174.8 (C-1''); ESI-MS m/z : 837 $[\text{M}+\text{Na}]^+$

A mixture of β -sitosterol (33) and stigmastrol (34): Colorless needles (CH_2Cl_2 -MeOH); IR ν_{\max} (ATR) 3427 (OH) cm^{-1} ; $^1\text{H NMR}$ (CDCl_3 , 200 MHz) δ : β -sitosterol: 0.67 (3H, s, H-18), 0.81 (3H, d, $J = 6.8$ Hz, H-26), 0.83 (3H, d, $J = 6.8$ Hz, H-27), 0.84 (3H, t, $J = 7.8$ Hz, H-29), 0.91 (3H, d, $J = 6.4$ Hz, H-21), 1.00 (3H, s, H-19), 3.50 (1H, m, H-3), 5.34 (1H, br d, $J = 5.2$ Hz, H-6); stigmastrol: 0.69 (3H, s, H-18), 0.81 (3H, d, $J = 6.8$ Hz, H-26), 0.83 (3H, d, $J = 6.8$ Hz, H-27), 0.84 (3H, t, $J = 7.8$ Hz, H-29), 0.91 (3H, d, $J = 6.4$ Hz, H-21), 1.00 (3H, s, H-19), 3.50 (1H, m, H-3), 5.00 (1H, dd, $J = 15.2, 8.0$ Hz, H-23), 5.15 (1H, dd, $J = 15.2, 8.0$ Hz, H-22), 5.34 (1H, br d, $J = 5.2$ Hz, H-6)

A mixture of 3-O- β -D-glucopyranosyl β -sitosterol (35) & 3-O- β -D-glucopyranosyl stigmastrol (36): Whitish solid; IR ν_{\max} (ATR) 3397 (OH) cm^{-1} ; $^1\text{H NMR}$ (pyridine-*d*₅, 400 MHz) δ : 3-O- β -D-glucopyranosyl β -sitosterol: 0.67 (3H, s, H-18), 0.88 (3H, d, $J = 7.6$ Hz, H-27), 0.91

(3H, t, $J = 8.2$ Hz, H-29), 0.93 (3H, d, $J = 8.4$ Hz, H-26), 0.95 (3H, s, H-19), 1.04 (3H, d, $J = 6.4$ Hz, H-21), 2.48 (1H, t, $J = 12.4$ Hz, H-4b), 2.74 (1H, dd, $J = 12.4, 2.6$ Hz, H-4a), 3.96 (1H, m, H-3), 3.98 (1H, m, 5'), 4.06 (1H, t, $J = 7.8$ Hz, H-2'), 4.29 (2H, t, $J = 5.2$ Hz, H-3' & 4'), 4.42 (1H, dd, $J = 12.0, 5.2$ Hz, H-6'b), 4.57 (1H, dd, $J = 12.0, 2.4$ Hz, H-6'a), 5.06 (1H, d, $J = 7.8$ Hz, H-1'), 5.36 (1H, d, $J = 4.8$ Hz, H-6); 3-*O*- β -D-glucopyranosyl stigmaterol: 0.67 (3H, s, H-18), 0.88 (3H, d, $J = 7.6$ Hz, H-27), 0.91 (3H, t, $J = 8.2$ Hz, H-29), 0.93 (3H, d, $J = 8.4$ Hz, H-26), 0.95 (3H, s, H-19), 1.04 (3H, d, $J = 6.4$ Hz, H-21), 2.48 (1H, t, $J = 12.4$ Hz, H-4b), 2.74 (1H, dd, $J = 12.4, 2.6$ Hz, H-4a), 3.96 (1H, m, H-3), 3.98 (1H, m, H-5'), 4.06 (1H, t, $J = 7.8$ Hz, H-2'), 4.29 (2H, t, $J = 5.2$ Hz, H-3' & H-4'), 4.42 (1H, dd, $J = 12.0, 5.2$ Hz, H-6'b), 4.57 (1H, dd, $J = 12.0, 2.4$ Hz, H-6'a), 5.05 (1H, dd, $J = 15.2, 8.4$ Hz, H-22), 5.06 (1H, d, $J = 7.8$ Hz, H-1'), 5.24 (1H, dd, $J = 15.2, 8.4$ Hz, H-23), 5.36 (1H, d, $J = 4.8$ Hz, H-6)

Isopropyl *O*- β -(6'-*O*-galloyl)glucopyranoside (37): Yellowish solid; $[\alpha]^{26}_D$: -36 (c 0.25, MeOH); UV (MeOH) λ_{max} ($\log \epsilon$) 215 (4.38), 275 (4.01) nm; IR ν_{max} (ATR) 3320 (OH), 1693 (ester), 1609, 1535, 1448 (aromatic ring) cm^{-1} ; ^1H NMR (CD_3OD , 400 MHz) δ : 1.18 (3H, d, $J = 6.0$ Hz, H-1), 1.20 (3H, d, $J = 6.0$ Hz, H-2), 3.18 (1H, m, H-3'), 3.37 (1H, m, H-4'), 3.39 (1H, m, H-5'), 3.55 (1H, m, 2'), 4.37 (1H, d, $J = 7.6$ Hz, H-1'), 4.38 (1H, dd, $J = 12.0, 5.8$ Hz, H-6'b), 4.52 (1H, dd, $J = 12.0, 2.4$ Hz, H-6'a), 7.07 (2H, s, H-1'' and H-3''); ^{13}C NMR (CD_3OD , 100 MHz) δ : 22.2 (C-1), 23.8 (C-2), 64.8 (C-6'), 71.8 (C-4'), 73.3 (C-3), 75.1 (C-3'), 75.4 (C-2'), 78.0 (C-5'), 103.0 (C-1'), 110.2 (C-1'' and C-3''), 121.2 (C-2''), 146.5 (C-4'', C-6''), 139.9 (C-5''), 168.4 (C-7''); ESI-MS m/z 375 $[\text{M}+\text{H}]^+$

4-Hydroxy-3-methoxyphenol 1-*O*- β -D-(2',6'-di-*O*-galloyl)glucoside (38): Yellowish solid; $[\alpha]^{26}_D$: -41 (c 0.12, MeOH); UV (MeOH) λ_{max} ($\log \epsilon$) 271 (4.67), 278 (4.32) nm; IR ν_{max} (ATR) 3369 (OH), 1697 (ester), 1613, 1513, 1449 (aromatic ring) cm^{-1} ; ^1H NMR (CD_3OD , 600 MHz) δ : 3.56 (3H, s, OCH_3 -3), 3.58 (1H, dd, $J = 9.6, 9.0$ Hz, H-4'), 3.75 (1H, t, $J = 9.0$ Hz, H-3'), 3.80 (1H, ddd, $J = 9.6, 6.6, 2.4$ Hz, H-5'), 4.49 (1H, dd, $J = 12.0, 2.4$ Hz, H-6'b), 4.64 (1H, dd, $J = 12.0, 6.6$ Hz, H-6'a), 4.95 (1H, d, $J = 8.1$ Hz, H-1'), 5.12 (1H, dd, $J = 9.0, 8.1$ Hz, H-2'), 6.44 (1H, d, $J = 2.8$ Hz, H-2), 6.45 (1H, d, $J = 7.8, 2.8$ Hz, H-6), 6.57 (1H, d, $J = 7.8$ Hz, H-5), 7.13 (4H, s, H-2'', H-6'', H-2''', and H-6'''), ^{13}C NMR (CD_3OD , 150 MHz) δ : 56.2 (OCH_3 -3), 64.8 (C-6'), 71.9 (C-4'), 75.5 (C-2'), 75.9 (C-5), 76.0 (C-3'), 103.2 (C-1'), 104.3 (C-2'), 110.3 (C-2'', C-6'' or C-2''', C-6'''), 110.4 (C-2''', C-6''' or C-2'', C-6''), 110.8 (C-6), 116.1 (C-5), 121.3 (C-1'' or C-1'''), 121.4 (C-1''' or C-1''), 140.1 (C-4'' and C-4'''), 143.6 (C-4), 146.6 (C-3'', C-5'' or C-3''', C-5'''), 146.7 (C-3''', C-5'' or C-3'', C-5''), 149.2 (C-3), 152.7 (C-1), 167.8 (C-7'' or C-7'''), 168.3 (C-7''' or C-7''); ESI-MS m/z 629 $[\text{M}+\text{Na}]^+$

3-Methoxy-4-hydroxyphenyl 1-*O*- β -D-(6'-*O*-galloyl)glucopyranoside (39): Whitish solid; $[\alpha]^{26}_D$: -39 (c 0.335, MeOH); UV (MeOH) λ_{max} ($\log \epsilon$) 205 (4.42), 275 (4.02) nm; IR ν_{max} (ATR) 3281 (OH), 1693 (C=O), 1610, 1508, 1448 (aromatic ring) cm^{-1} ; ^1H NMR (CD_3OD , 400 MHz) δ : 3.43 (1H, m, H-2'), 3.44 (1H, m, H-4'), 3.47 (1H, m, H-3'), 3.70 (3H, s, OCH_3 -3), 3.70 (1H, m, H-5'), 4.42 (1H, dd, $J = 12.0, 6.8$ Hz, H-6'b), 4.59 (1H, dd, $J = 12.0, 2.0$ Hz, H-6'a), 4.72 (1H, d, $J = 7.2$ Hz, H-1'), 6.56 (1H, dd, $J = 8.5, 2.5$ Hz, H-6), 6.62 (1H, d, $J = 8.5$ Hz, H-5), 6.70 (1H, d, $J = 2.5$ Hz, H-2), 7.09 (2H, s, H-2'' and H-6''); ^{13}C NMR (CD_3OD , 100 MHz) δ : 56.3 (OCH_3 -3), 65.0 (C-6'), 71.8 (C-4'), 75.0 (C-2'). 75.7 (C-5'), 77.8 (C-3'), 103.9 (C-2), 104.0 (C-1'), 110.17 (C-6), 110.21 (C-2'', C-6''), 116.1 (C-5), 121.4 (C-1''), 140.0 (C-4''), 143.1 (C-4), 146.6 (C-3'' and C-5''), 149.2 (C-3), 152.7 (C-1), 168.3 (C-7''); ESI-MS m/z 455 $[\text{M}+\text{H}]^+$

1,2,3,4,6-Penta-*O*-galloyl- β -D-glucose (40): Yellowish solid; $[\alpha]^{26}_D$: $+34$ (c 0.36, MeOH); UV (MeOH) λ_{max} ($\log \epsilon$) 215 (4.98), 280 (4.64) nm; IR ν_{max} (ATR) 3355 (OH), 1695 (C=O), 1610, 1535, 1448 (aromatic ring) cm^{-1} ; ^1H NMR (CD_3OD , 200 MHz) δ : 4.40 (1H, t, $J = 9.8$ Hz, H-6b), 4.45 (1H, t, $J = 9.8$ Hz, H-6a), 4.50 (1H, t, $J = 9.8$ Hz, H-5), 5.59 (1H, m, H-2), 5.62 (1H, m, H-4), 5.91 (1H, t, $J = 9.8$ Hz, H-3), 6.23 (1H, d, $J = 8.2$ Hz, H-1), 6.90 (2H, s, galloyl group), 6.95 (2H, s, galloyl group), 6.98 (2H, s, galloyl group), 7.05 (2H, s, galloyl group), 7.11 (2H, s, galloyl group); ESI-MS m/z 963 $[\text{M}+\text{Na}]^+$

Corilagin (41): Yellowish solid; $[\alpha]^{25}_D$: + 173 (c 0.5, acetone); UV (MeOH) λ_{max} (log ϵ) 215 (4.61), 270 (4.28) nm; IR ν_{max} (ATR) 3349 (OH), 1712 (C=O), 1610, 1518, 1447 (aromatic ring) cm^{-1} ; 1H NMR (acetone- d_6 , 400 MHz) δ : 4.08 (1H, br s, H-2), 4.11 (1H, dd, J = 11.0, 8.2 Hz, H-6b), 4.47 (1H, br s, H-4), 4.52 (1H, t, J = 9.6 Hz, H-5), 4.84 (1H, br s, H-3), 4.97 (1H, t, J = 11.0 Hz, H-6a), 6.38 (1H, d, J = 1.6 Hz, H-1), 6.70 (1H, s, H-3'' or H-3'''), 6.85 (1H, s, H-3''' or H-3''), 7.13 (2H, s, H-2' and H-6'); ^{13}C NMR (acetone- d_6 , 100 MHz) δ : 62.9 (C-4), 65.0 (C-6), 69.6 (C-2), 71.2 (C-3), 76.3 (C-5), 94.8 (C-1), 108.3 (C-3'' or C-3'''), 110.6 (C-3''' or C-3''), 111.6 (C-2' & 6'), 116.5 (C-1'' or C-1'''), 117.2 (C-1''' or C-1''), 121.5 (C-1'), 126.3 (C-2'' or C-2'''), 126.4 (C-2''' or C-2''), 137.4 (C-6'''), 137.9 (C-6''), 139.9 (C-4'), 145.4 (C-4'' or C-4'''), 145.6 (C-3' or C-5'), 146.0 (C-4''' or C-4''), 146.5 (C-5' and C-3'), 165.8 (C-7'), 167.8 (C-7''), 169.2 (C-7'''); ESI-MS m/z 657 [M+Na]⁺

1,4,6-Tri-O-galloyl- β -D-glucose (42): Yellowish solid; $[\alpha]^{25}_D$: -34 (c 0.365, acetone); IR ν_{max} (ATR) 3390 (OH), 1704 (C=O), 1612, 1533, 1450 (aromatic ring) cm^{-1} ; 1H NMR (acetone- d_6 , 400 MHz) δ : 3.73 (1H, t, J = 9.9 Hz, H-2), 3.99 (1H, t, J = 9.9 Hz, H-3), 4.14 (1H, ddd, J = 9.9, 5.2, 1.8 Hz, H-5), 4.19 (1H, dd, J = 12.3, 5.2 Hz, H-6b), 4.45 (1H, dd, J = 12.3, 1.8 Hz, H-6a), 5.26 (1H, t, J = 9.9 Hz, H-4), 5.85 (1H, d, J = 9.9 Hz, H-1), 7.13 (2H, s, H-2''' and H-6'''), 7.16 (2H, s, H-2'' and H-6''), 7.19 (2H, s, H-2' and H-6'); ^{13}C NMR (acetone- d_6 , 100 MHz) δ : 64.1 (C-6), 72.3 (C-4), 74.6 (C-5), 74.9 (C-2), 76.3 (C-3), 96.2 (C-1), 110.8 (C-2''' and C-6'''), 111.0 (C-2'' and C-6''), 111.1 (C-2' and C-6'), 121.6 (C-1'), 122.2 (C-1''), 122.3 (C-1'''), 139.6 (C-4'''), 139.7 (C-4''), 140.1 (C-4'), 146.65 (C-3''' and C-5'''), 146.72 (C-3'' and C-5''), 146.8 (C-3' and C-5'), 166.1 (C-7'), 166.7 (C-7''), 167.1 (C-7'''); ESI-MS m/z 659 [M+Na]⁺

1,3,6-Tri-O-galloyl- β -D-glucose (43): Yellowish solid; IR ν_{max} (ATR) 3354 (OH), 1702 (C=O), 1613, 1539, 1451 (aromatic ring) cm^{-1} ; 1H NMR (CD₃OD, 400 MHz) δ : 3.77 (1H, t, J = 8.9, Hz, H-2), 3.80 (1H, t, J = 8.9 Hz, H-4), 3.88 (1H, ddd, J = 8.9, 4.8, 2.5 Hz, H-5), 4.43 (1H, dd, J = 12.0, 4.8 Hz, H-6b), 4.58 (1H, dd, J = 12.0, 2.5 Hz, H-6a), 5.58 (1H, t, J = 8.9 Hz, H-3), 5.82 (1H, d, J = 8.9 Hz, H-1), 7.10 (2H, s, H-2''' and H-6'''), 7.14 (2H, s, H-2'' and H-6''), 7.16 (2H, s, H-2' and H-6'); ESI-MS m/z 659 [M+Na]⁺

Gallic acid 4-O- β -D-(6'-O-galloyl)-glucose (44): Yellowish solid; $[\alpha]^{25}_D$: -6 (c, 0.145, acetone); IR ν_{max} (ATR) 3289 (OH), 1699 (C=O), 1612, 1525, 1452 (aromatic ring) cm^{-1} ; 1H NMR (CD₃OD, 600 MHz) δ : 3.48 (1H, dd, J = 9.6, 7.8 Hz, H-3), 3.52 (1H, t, J = 9.6 Hz, H-4), 3.54 (1H, t, J = 7.8 Hz, H-2), 3.68 (1H, ddd, J = 9.6, 5.4, 2.4 Hz, H-5), 4.43 (1H, dd, J = 8.0, 5.4 Hz, H-6b), 4.61 (1H, dd, J = 8.0, 2.4 Hz, H-6a), 4.70 (1H, d, J = 7.8 Hz, H-1), 7.05 (2H, s, H-3' and H-5'), 7.12 (2H, s, H-2'' and H-6''); ^{13}C NMR (CD₃OD, 150 MHz) δ : 64.4 (C-6), 71.2 (C-4), 75.0 (C-2), 76.6 (C-5), 77.5 (C-3), 107.5 (C-1) 110.2 (C-3' and C-5'), 110.3 (C-2'' or C-6'''), 110.4 (C-6'' or C-2''), 121.3 (C-4' and C-1''), 137.5 (C-1'), 140.0 (C-4''), 146.5 (C-3'' and C-5''), 151.1 (C-2' and C-6'), 168.4 (C-7''), 174.9 (C-7'); ESI-MS m/z 485 [M+H]⁺